Cytosorbents (NASDAQ:CTSO) Releases Earnings Results, Misses Expectations By $0.02 EPS

Cytosorbents (NASDAQ:CTSO) issued its quarterly earnings results on Wednesday. The medical research company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02), Zacks reports. Cytosorbents had a negative return on equity of 191.30% and a negative net margin of 31.85%.The business had revenue of $8.86 million for the quarter, compared to analysts’ expectations of $9.40 million.

Here are the key takeaways from Cytosorbents’ conference call:

• CytoSorbents reported Q1 2026 revenue of $8.9 million, up 2% year over year, with growth in direct international markets outside Germany offset by weakness in Germany and disruptions in the Middle East.
• International direct sales grew 13% year over year, which management said reflected better physician awareness, stronger execution, and improving adoption in key accounts.
• Gross margin was 69%, and the company said the slight decline was intentional because it slowed production to reduce inventory and improve working capital.
• The company said it now has clear FDA direction for DrugSorb-ATR, including a planned pre-submission for DOAC removal, though the new De Novo filing for ticagrelor removal may slip to late 2026 or early 2027 due to additional mechanistic data requests.
• Management highlighted growing clinical evidence for DrugSorb-ATR and CytoSorb, including STAR-T publication results showing the device was safe and reduced severe bleeding in CABG patients, plus upcoming presentations at major cardiovascular conferences.

Cytosorbents Stock Performance

Cytosorbents stock traded down $0.03 during mid-day trading on Thursday, hitting $0.54. The company had a trading volume of 305,628 shares, compared to its average volume of 54,783. The company has a current ratio of 2.13, a quick ratio of 1.58 and a debt-to-equity ratio of 2.82. Cytosorbents has a 12-month low of $0.50 and a 12-month high of $1.39. The company’s fifty day moving average is $0.64 and its 200-day moving average is $0.68. The company has a market capitalization of $33.97 million, a price-to-earnings ratio of -2.85 and a beta of 1.43.

Institutional Investors Weigh In On Cytosorbents

Several hedge funds have recently bought and sold shares of the stock. Citadel Advisors LLC boosted its position in Cytosorbents by 127.3% in the 3rd quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock worth $61,000 after purchasing an additional 36,790 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Cytosorbents by 149.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock worth $63,000 after buying an additional 37,519 shares during the period. Vanguard Group Inc. raised its stake in shares of Cytosorbents by 3.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock worth $2,059,000 after buying an additional 79,535 shares during the period. Avenir Corp raised its stake in shares of Cytosorbents by 2.9% during the 4th quarter. Avenir Corp now owns 5,230,099 shares of the medical research company’s stock worth $3,343,000 after buying an additional 147,261 shares during the period. Finally, CIBC Bancorp USA Inc. acquired a new position in shares of Cytosorbents during the 3rd quarter worth approximately $161,000. Hedge funds and other institutional investors own 32.87% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on CTSO shares. D. Boral Capital reiterated a “buy” rating and issued a $10.00 target price on shares of Cytosorbents in a research report on Thursday, March 26th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cytosorbents in a research report on Wednesday, April 8th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $5.38.

Cytosorbents Company Profile

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.